BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35898885)

  • 1. The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study.
    Hu J; Chen Z; Lv J; Zheng Z; Bei Y; Chen X; Zheng L; Song W; Xu Y
    Front Oncol; 2022; 12():905422. PubMed ID: 35898885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
    Yu N; Cheng G; Li J; Liang J; Zhang T; Deng L; Liu W; Wang J; Zhai Y; Wang W; Xiao Z; Zhou Z; Chen D; Feng Q; Bi N; Wang X
    Curr Cancer Drug Targets; 2023; 23(8):653-662. PubMed ID: 36924100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Thai Hoa NT; Quang Huy H
    Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.
    Tian X; Xuan Y; Wu R; Gao S
    Cancer Manag Res; 2020; 12():3323-3329. PubMed ID: 32494195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.
    Liang J; E M; Wu G; Zhao L; Li X; Xiu X; Li N; Chen B; Hui Z; Lv J; Fang H; Tang Y; Bi N; Wang W; Zhai Y; Li T; Chen D; Zou S; Lu N; Perez-Rodríguez R; Zheng J; Wang L
    Onco Targets Ther; 2013; 6():1589-96. PubMed ID: 24235844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
    J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
    Cao Y; Deng L; Lian S; Jiang Y
    J BUON; 2019; 24(5):2013-2019. PubMed ID: 31786869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
    Huang J; Zou Q; Qian D; Zhou L; Yang B; Chu J; Pang Q; Wang K; Zhang F
    Onco Targets Ther; 2017; 10():5835-5841. PubMed ID: 29263680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy.
    Du XX; Yu R; Wang ZF; Du DC; Liu QY; Wang RM; Kang SR; Yang H
    Bosn J Basic Med Sci; 2019 May; 19(2):186-194. PubMed ID: 30877837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis.
    Zhang Y; Wang J; Cui D; Kong L; Wang P; Fu Z; Su M; Li B; Liang J
    BMC Gastroenterol; 2022 Dec; 22(1):526. PubMed ID: 36528571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement and prognosis analysis of nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
    Luan W; Yuan H; Hou W; Li J; Liu L
    Am J Transl Res; 2022; 14(8):5630-5640. PubMed ID: 36105032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.
    Chen NB; Qiu B; Zhang J; Qiang MY; Zhu YJ; Wang B; Guo JY; Cai LZ; Huang SM; Liu MZ; Li Q; Hu YH; Li QW; Liu H
    Cancer Res Treat; 2020 Jan; 52(1):31-40. PubMed ID: 31048664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer.
    Qi S; Mao Y; Jiang M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1115-1123. PubMed ID: 31502113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
    Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
    Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.
    Ao M; Li P; Sun D; Li X; Xu S; Hao Y
    J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study.
    Guler OC; Oymak E; Yazici G; Akagunduz OO; Cetinayak O; Erpolat P; Aksoy A; Duzova M; Yildirim BA; Kurt M; Canyilmaz E; Yavas G; Akyurek S; Oksuz DC; Saglam EK; Celik OK; Ozyar E; Cengiz M; Onal C
    Oncol Res; 2023; 31(3):299-306. PubMed ID: 37305394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
    Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
    Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
    Zong JF; Liang QD; Lu QJ; Liu YH; Xu HC; Chen BJ; Guo QJ; Xu Y; Hu CR; Pan JJ; Lin SJ
    BMC Cancer; 2021 Nov; 21(1):1274. PubMed ID: 34823489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.